Non-pegylated Liposomal Doxorubicin (Myocet ®) Plus Docetaxel (Taxotere ®) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study

被引：0
|
作者：
Imperatori, L. [1 ]
Lippe, P. [1 ]
Trapuzzano, C. [1 ]
Laici, G. [1 ]
Cappelletti, C. [1 ]
Tamburrano, T. [1 ]
Mattioli, R. [1 ]
机构：
[1] Osped Santa Croce, Fano, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71517-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [21] Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE
    de la Fouchardiere, C.
    Largillier, R.
    Goubely, Y.
    Hardy-Bessard, A. -C.
    Slama, B.
    Cretin, J.
    Orfeuvre, H.
    Paraiso, D.
    Bachelot, T.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1959 - 1963
  • [22] Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
    S. Del Barco
    R. Colomer
    L. Calvo
    I. Tusquets
    E. Adrover
    P. Sánchez
    J. Rifà
    J. De la Haba
    J. A. Virizuela
    Breast Cancer Research and Treatment, 2009, 116 : 351 - 358
  • [23] Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
    Del Barco, S.
    Colomer, R.
    Calvo, L.
    Tusquets, I.
    Adrover, E.
    Sanchez, P.
    Rifa, J.
    De la Haba, J.
    Virizuela, J. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (02) : 351 - 358
  • [24] Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer
    Aihara, T
    Takatsuka, Y
    Itoh, K
    Sasaki, Y
    Katsumata, N
    Watanabe, T
    Noguchi, S
    Horikoshi, N
    Tabei, T
    Sonoo, H
    Hiraki, S
    Inaji, H
    ONCOLOGY, 2003, 64 (02) : 124 - 130
  • [25] DOCETAXEL IN COMBINATION WITH NON PEGYLATED LIPOSOME-ENCAPSULATED DOXORUBICIN (MYOCET®) FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC) PATIENTS: A PHASE II CLINICAL STUDY
    Coltelli, L.
    Allegrini, G.
    Barletta, M. T.
    Giuntini, N.
    Safina, V.
    Barsanti, G.
    Bona, E.
    Di Marsico, R.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 72 - 72
  • [26] Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen.
    Guastalla, JP
    Hardy-Bessard, AC
    Geay, JF
    Cure, H
    Ray-Coquard, I
    Paraiso, D
    Pujade-Lauraine, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 81S - 81S
  • [27] Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Moreno-Nogueira, J
    Casal, J
    Castellanos, J
    Lizón, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [28] Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)
    Rosati, M. S.
    Raimondi, C.
    Baciarello, G.
    Grassi, P.
    Giovannoni, S.
    Petrelli, E.
    Basile, M. L.
    Girolami, M.
    Di Seri, M.
    Frati, L.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 315 - 320
  • [29] Navelbine® (NVB) alterning oral and IV plus Myocet® as first line chemotherapy of metastatic breast cancer (MBC):: Phase II study
    Lorusso, V.
    Spada, M.
    Cassano, G.
    Guida, M.
    Latorre, A.
    Misino, A.
    Calabrese, R.
    Giampaglia, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 16 - 16
  • [30] Non-pegylated liposomal doxorubicin in metastatic breast cancer (MBC) - Results from an Austrian post marketing surveillance programme
    Steger, G. G.
    Mlineritsch, B.
    Bartsch, R.
    Pluschnig, U.
    Petru, E.
    Peintinger, F.
    Sevelda, P.
    Greil, R.
    ONKOLOGIE, 2010, 33 : 55 - 55
12345